SLV-213

N/A

Report date: 2024/07/09 20:00:06
NME

Base Information

Drug NameSLV-213
Drug Alias NameSLV-213SLV213K-777(Selva Therapeutics)K11777K-11777 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCathepsin L inhibitors
TargetsCathepsin L
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San DiegoTexas A&M UniversitySelva Therapeutics Inc +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesSelva Therapeutics IncUniversity Of California San DiegoTexas A&M University
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A